Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Open accessThe DOI matches its Crossref record; 159 of the 165 references it cites were found in a registry or an index.
Abstract
Human epidermal growth factor 2 (HER2) is a tyrosine kinase receptor that interacts with multiple signaling pathways related to cellular growth and proliferation. Overexpression or amplification of HER2 is linked to various malignancies, and there have been decades of research dedicated to targeting HER2. Despite the landmark ToGA trial, progress in HER2-positive gastrointestinal malignancies has been hampered by drug resistance. This review examines current HER2 expression patterns and therapies for gastroesophageal, colorectal, biliary tract, and small bowel cancers, while dissecting potential resistance mechanisms that limit treatment effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Select mechanisms of HER2 targeted resistance: (1) Acquired resistance to HER2 therapy involves compensatory activation of PI3K/AKT/mTOR and MAPK/ERK pathways, facilitated by various mechanisms such as MET amplification interacting with HGF [A], overexpression of HER2-family ligands (EGF, AREG, NRG1) [B], upregulation of phosphorylated IGF-1R [C], activation of Src-promoting signaling pathways [D], PTEN loss-of-function mutation causing PIP3 dysregulation [E], and co-amplifications of CDK6, CCND1, CCNE1 driving cell-cycle progression [F]. (2) The heterogeneous expression of HER2 in tumors contributes to primary and acquired resistance to HER2-targeted therapies. Progressive loss of HER2 positivity is a key factor in acquired resistance. Intratumoral heterogeneity is also common in gastric cancer, even before HER2 treatment (3) Mutations in HER2, together with HER2 and HER3 mutations, activate the PI3K–AKT pathway [G]. The generation of ERBB2d16 (HER2d16), a variant lacking exon 16′s extracellular domain, stabilizes homodimers and activates downstream signaling [H]. Overexpression of p95HER2 produces a truncated HER2 form without the extracellular domain [I] (4) Excessive mucin 4 (MUC4) expression and the CD44–polymeric hyaluronan complex can cause inhibition of Trastuzumab binding to HER2. Figure Abbreviations: AREG Amphiregulin; CCNE1 Cyclin E1 gene; CDK Cyclin; EGF/R Epidermal growth factor/receptor; FGFR3 Fibroblast growth factor receptor 3; HER1/2/3 Human epidermal growth factor rector 1/2/3; HGF Hepatocyte growth factor; IGF-1R Insulin-like growth factor 1 receptor; MET Mesenchymal epithelial transition; NRG1 Neuregulin 1; SRC Proto-oncogene tyrosine-protein kinase Src; PI3K/AKT phosphoinositide 3-kinase/AKT; PTEN phosphatase and tensin homolog; Ras/RAF/MEK/ERK Ras/Raf/MEK/extracellular signal-regulated kinase; Rb Retinoblastoma protein; RTK Receptor tyrosine kinase.](https://figures.cochat.ai/paper-figures/fa585ed2daf9434e85ff16b911cd8db1/resistance-to-anti-her2-therapies-in-gastrointestinal-malignancies-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In HER2-amplified tumors, coexisting PIK3CA mutations may reduce the efficacy of HER2-targeted therapies, such as trastuzumab, by maintaining downstream PI3K/AKT signaling despite receptor inhibition [48].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · cited 2×
“The addition of trastuzumab resulted in a significant survival benefit (median OS 13.8 months vs. 11.1 months; p = 0.046) (Table 1) [20].”
BackgroundInfluentialComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · cited 3×
“Multiple studies have identified common amplifications in CCNE1 , CDK6 , EGFR , MET , and MYC , and mutations in the PTEN and PIK3CA gene [63,107,108].”
BackgroundTargeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676 · cited 1×
“In order to exert its antitumoral function, trastuzumab emtansine (T-DM1) binds to the HER2 receptor and is internalized by the target tumor cells [153].”
BackgroundGastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., & Smyth, E. C. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.004 · Cited by 1,503 · cited 2×
“The European Society of Medical Oncology (ESMO) recommends HER2 testing for metastatic GC, while the American Society of Clinical Oncology (ASCO) recommends HER2 testing on either primary or metastatic lesions for all patients with a diagnosed GC who are able to tolerate combination therapy [92,93].”
BackgroundThe ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353 · cited 1×
“[6,7].”
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333 · cited 2×
“DESTINY-GASTRIC01 utilized T-DXd versus standard chemotherapy for HER2-positive advanced GC who progressed on prior therapies including trastuzumab, resulting in FDA approval [70].”
BackgroundMethodInfluentialAssessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187 · cited 1×
“A large-scale validation study established the current guidelines for HER2 testing in gastric cancer, which was then utilized for colorectal, biliary tract, and small bowel cancer [11].”
BackgroundOgitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177 · cited 1×
“This ADC utilizes a HER2-targeting antibody (trastuzumab) as a vehicle to deliver a topoisomerase I inhibitor (deruxtecan) directly to HER2-expressing cancer cells [53].”
BackgroundTargeting HER2-positive breast cancer: advances and future directions
Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160 · cited 1×
“Tyrosine kinase inhibitors (TKIs) are orally administered small molecules that target the intracellular catalytic kinase domain of HER2 by competing with ATP, inhibiting phosphorylation and blocking downstream signaling cascades [44].”
Background
Research works printed but not linked: 1
- (2024, May 04). Phase 2 Study of ZW25 Plus First-Line Combination Chemotherapy in HER2-Expressing Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), and Colorectal Cancer (CRC). Available online: https://adisinsight.springer.com/trials/700306473.
Cited by
Wang, P., Chao, W., & Lee, N.-R. (2024) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2024.09.006 · Cited by 25
Miski, H., Krupa, K., Budzik, M. P., Deptała, A., & Badowska-Kozakiewicz, A. M. (2025) · Biomedicines · doi:10.3390/biomedicines13051153 · Cited by 5
“HER2 amplification is present in 3–5% of colorectal cancers and is associated with more aggressive tumor behavior and higher recurrence rates [38].”
Evolving precision: Updates in targeted therapy for cholangiocarcinoma
Tesini, G., Ibrahim, H., Rimassa, L., & Braconi, C. (2025) · Hepatology · doi:10.1097/hep.0000000000001541 · Cited by 7
Jiang, Q. J., Li, G., Li, H., Jiang, X., & Xiang, D. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105152 · Cited by 4
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“In HER2-amplified tumors, coexisting PIK3CA mutations may reduce the efficacy of HER2-targeted therapies, such as trastuzumab, by maintaining downstream PI3K/AKT signaling despite receptor inhibition [48].”
Metadata
- Authors
- Mo, C., Sterpi, M., Jeon, H., & Bteich, F.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Bteich, Fernand
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-08-15
- Volume
- 16
- Issue
- 16
- Pages
- 2854
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11352490
- OpenAlex
- W4401643100
- Cited by
- 8
- References
- 165
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 1
- FWCI
- 0.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- HER2, HER2-targeted therapy, drug resistance, gastrointestinal cancer, HER2-positive gastric cancer, HER2-positive colorectal cancer, biliary tract cancer, small intestine neoplasms, HER2 overexpression, tyrosine kinase inhibitors, resistance mechanisms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies. https://app.cochat.ai/papers/10.3390/cancers16162854
- The paper
- Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024). Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies. Cancers. https://doi.org/10.3390/cancers16162854
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.